Forward Therapeutics – a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders – recently announced a $50 million Series A financing. BVF Partners LP led the funding with participation from other leading life sciences investors RA Capital Management and OrbiMed.
The proceeds from the Series A financing will enable Forward to advance its portfolio of novel, small-molecule immunology medicines towards clinical development. And Forward Therapeutics is the first company to partner with Curie.Bio, a new model for venture capital in biotech focused on helping founders launch therapeutics companies.
KEY QUOTES:
“This Series A financing round is a significant milestone for Forward Therapeutics. We are grateful to be supported by leading life sciences investors who recognize the potential of our novel therapies to impact the lives of millions of people living with chronic immunological and inflammatory conditions. We would also like to thank the Curie.Bio team for their support which helped create an efficient operational model and accelerate our pipeline.”
— Toufike Kanouni, chief executive officer of Forward Therapeutics
“Our programs target key immunology nodes, aiming to reduce inflammation, promote healing and restore quality of life. Our goal is to expand global patient access to high quality medicines. We appreciate our investors support to help achieve our vision.”
— Ewan Taylor, chief scientific officer of Forward Therapeutics
